An historical perspective on Endel Tulving's episodic-semantic distinction.

Neuropsychologia

School of Psychology, University of East Anglia, Norwich, UK; Center for Vital Longevity and School of Behavioral and Brain Sciences, University of Texas, Dallas, USA.

Published: March 2020

The distinction between episodic and semantic memory, proposed by Endel Tulving in 1972, remains a key concept in contemporary Cognitive Neuroscience. Here we review how this distinction evolved in Tulving's writings over the years. Crucially, from 1972 onward, he argued that the two forms of memory were inter-dependent and that their interaction was an essential feature of normal episodic memory function. Moreover, later elaborations of the theory clearly proposed that these interactions formed the basis of normal declarative memory functioning. A later but crucial aspect of Tulving's contribution was his stress on the importance of subjective experience, which, according to him, "should be the ultimate object of interest, the central aspect of remembering that is to be explained and understood". We relate these and his numerous other ideas to current perspectives about the organization and function of human memory.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropsychologia.2020.107366DOI Listing

Publication Analysis

Top Keywords

memory
5
historical perspective
4
perspective endel
4
endel tulving's
4
tulving's episodic-semantic
4
episodic-semantic distinction
4
distinction distinction
4
distinction episodic
4
episodic semantic
4
semantic memory
4

Similar Publications

Background: The imbalance of glutamate (Glu) and gamma-aminobutyric acid (GABA) neurotransmitter system plays a crucial role in the pathogenesis of Alzheimer's disease (AD). Riluzole is a Glu modulator originally approved for amyotrophic lateral sclerosis that has shown potential neuroprotective effects in various neurodegenerative disorders. However, whether riluzole can improve Glu and GABA homeostasis in AD brain and its related mechanism of action remain unknown.

View Article and Find Full Text PDF

Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity.

Mol Cancer

January 2025

Department of Medicine, Section of Epidemiology and Population Sciences, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA.

Lipid nanoparticles (LNPs) for mRNA delivery have advanced significantly, but LNP-mediated DNA delivery still faces clinical challenges. This study compared various LNP formulations for delivering DNA-encoded biologics, assessing their expression efficacy and the protective immunity generated by LNP-encapsulated DNA in different models. The LNP formulation used in Moderna's Spikevax mRNA vaccine (LNP-M) demonstrated a stable nanoparticle structure, high expression efficiency, and low toxicity.

View Article and Find Full Text PDF

Background: Physical activity (PA) interventions have been shown to yield positive effects on cognitive functions. However, it is unclear which type of PA intervention is the most effective in children and adolescents with Neurodevelopmental Disorders (NDDs). This study aimed to compare the effectiveness of different types of PA interventions on cognitive functions in children and adolescents with NDDs, with additional analyses examining intervention effects across specific NDD types including attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).

View Article and Find Full Text PDF

Background: Sleep is an active process that affects human health and quality of life. Sleep is essential for learning and memory consolidation. Good sleep is required for good academic performance.

View Article and Find Full Text PDF

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity.

J Transl Med

January 2025

Department of Medical Oncology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Anhui Provincial Cancer Hospital, Hefei, 230031, Anhui, China.

Background: Agonistic monoclonal antibodies targeting 4-1BB/CD137 have shown preclinical promise, but their clinical development has been limited by severe liver toxicity or limited efficacy. Therefore, a safe and efficient immunostimulatory molecule is urgently needed for cancer immunotherapy.

Methods: A novel anti-MSLN×4-1BB bispecific antibody (bsAb) was generated via antibody engineering, and its affinity and activity were detected via enzyme-linked immunosorbent assay (ELISA), flow cytometry, and T-cell activation and luciferase reporter assays.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!